International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Hypofractionated radiotherapy for favorable risk prostate cancer.
Since the recognition that prostate cancer probably has a low alpha/beta ratio, hypofractionated radiotherapy has become an attractive treatment option for localized prostate cancer. However, there is little experience with the use of hypofractionation delivering a high biologically equivalent dose. We report our experience with high-dose hypofractionated radiotherapy. ⋯ This hypofractionated regimen provides excellent biochemical control in favorable risk prostate cancer with an acceptable rate of late toxicity. Further studies exploring this hypofractionation regimen are warranted.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
RapidArc radiation therapy: first year experience at the University of Alabama at Birmingham.
To evaluate treatment planning and delivery for patients treated during our initial year of experience with RapidArc radiation therapy. ⋯ RapidArc plans have quality comparable to our standard SG-DMLC IMRT technique, and are delivered with similar accuracy in shorter time.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Multicenter StudyChemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. ⋯ The dose-dense regimen of TMZ administered in a 1-week on/1-week off schedule resulted in acceptable nonhematologic toxicity. Compared with data from the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981-22981/CE.3, patients with an unmethylated MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule regarding the median progression-free survival and overall survival. In contrast, data are promising for patients with a methylated MGMT promoter.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
To determine the short- and medium-term effects of a single high-dose-rate brachytherapy fraction of 15 Gy and hypofractionated external beam radiation therapy for prostate cancer. ⋯ Treatment is well tolerated in the short and medium term, with low toxicity and encouraging early indicators of disease control.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
To investigate factors associated with Grade >or=3 radiation pneumonitis (RP) in patients with lung tumors treated with stereotactic body radiotherapy (SBRT). ⋯ Only the latency period was a significant factor in the development of RP. No pretreatment clinical or dosimetric factors were significantly associated with Grade >or=3 RP. Patients, especially those with severe pulmonary comorbidities, should be carefully observed for the graphical appearance of RP within a few months during the follow-up period after SBRT.